Online inquiry

IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7792MR)

This product GTTS-WQ7792MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets env gene. The antibody can be applied in AIDS research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_579894.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 155971
UniProt ID P04578
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7792MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1723MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15982MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ6057MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ5567MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ9804MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ9582MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ10578MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ15624MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAY-736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW